- Gain Therapeutics Inc GANX has presented new preclinical data from its Parkinson's and Alzheimer's Disease programs.
- These results were highlighted at the International Conference on Alzheimer's (AD) and Parkinson's Diseases (PD).
- The data shows that improving the lysosomal function through enhanced glucocerebrosidase (GCase) levels and activity can improve key pathological features in α-synucleinopathies and AD.
- Related: Gain Therapeutics Stock Surges On Positive Preclinical Readout For Neurodegenerative Disease Drugs.
- Orally bioavailable and brain-penetrant lead structurally targeted allosteric regulators (STARs) reduce neurotoxicity derived from the accumulation of toxic oligomeric species of Aβ and α-synuclein.
- In mouse models, treatment with the STAR small molecule resulted in a decrease in neurotoxicity, motor deficit, neuroinflammation, and increase of neuronal survival.
- Price Action: GANX shares are up 3.94% at $3.43 during the market session on the last check Tuesday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralAlzheimer's diseaseBriefsParkinson’s DiseasePreclinical Phase